Integration of metabolic activation with a predictive toxicogenomics signature to classify genotoxic versus nongenotoxic chemicals in human TK6 cells

Environmental and Molecular Mutagenesis

Volumn 56, Issue 6, 2015, Pages 520-534

  Buick, Julie K ^a   Moffat, Ivy ^a   Williams, Andrew ^a   Swartz, Carol D ^b   Recio, Leslie ^b   Hyduke, Daniel R ^c,d   Li, Heng Hong ^d   Fornace, Albert J ^d   Aubrecht, Jiri ^e   Yauk, Carole L ^a  

^a HEALTH CANADA   (Canada)

^b INTEGRATED LABORATORY SYSTEMS   (United States)

^c Utah State University   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

Author keywords

Gene expression microarray; Genetic toxicology; Genomic biomarker; Micronucleus; TGx 28.65 classifier

Indexed keywords

AFLATOXIN B1; BENZO[A]PYRENE; BIOLOGICAL MARKER; DEXAMETHASONE; DIMETHYL SULFOXIDE; PHENOBARBITAL; TOXIC SUBSTANCE; CISPLATIN; GENETIC MARKER; MUTAGENIC AGENT;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TOXICOLOGY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LYMPHOBLASTOID CELL LINE; METABOLIC ACTIVATION; MICROARRAY ANALYSIS; MICRONUCLEUS; MICRONUCLEUS TEST; NONHUMAN; RAT; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC MARKER; PROCEDURES; REPRODUCIBILITY; TOXICOGENETICS;

RATTUS;

ACTIVATION, METABOLIC; AFLATOXIN B1; ANIMALS; APOPTOSIS; BENZO(A)PYRENE; CELL LINE; CELL SURVIVAL; CISPLATIN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MICRONUCLEUS TESTS; MUTAGENS; PHENOBARBITAL; RATS; REPRODUCIBILITY OF RESULTS; TOXICOGENETICS;

EID: 84937023786     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21940     Document Type: Article

References (27)

1. Amundson SA, Do KT, Vinikoor L, Koch-Paiz CA, Bittner ML, Trent JM, Meltzer P, Fornace AJ Jr. 2005. Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 24:4572-4579.
2. Boehme K, Dietz Y, Hewitt P, Mueller SO. 2011. Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci 122:185-197.
3. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al. 2001. Minimum information about a microarray experiment (MIAME) - Toward standards for microarray data. Nat Genet 29:365-371.
4. Dickinson DA, Warnes GR, Quievryn G, Messer J, Zhitkovich A, Rubitski E, Aubrecht J. 2004. Differentiation of DNA reactive and non-reactive genotoxic mechanisms using gene expression profile analysis. Mutat Res 549:29-41.
5. Doktorova TY, Yildirimman R, Vinken M, Vilardell M, Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, Li R, et al. 2013. Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis 34:1393-1402.
6. Ellinger-Ziegelbauer H, Fostel JM, Aruga C, Bauer D, Boitier E, Deng S, Dickinson D, Le Fevre AC, Fornace AJ, Jr, Grenet O, et al. 2009. Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol Sci 110:341-352.
7. FDA. 2007. Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients (Redbook 2000) (revised). Center for Food Safety and Applied Nutrition (U.S. FDA).
8. Godderis L, Thomas R, Hubbard AE, Tabish AM, Hoet P, Zhang L, Smith MT, Veulemans H, McHale CM. 2012. Effect of chemical mutagens and carcinogens on gene expression profiles in human TK6 cells. PLoS One 7:e39205.
9. Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J, Charlab R, Close S, Cornu-Artis C, Essioux L, et al. 2010. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov 9:435-445.
10. Hu T, Gibson DP, Carr GJ, Torontali SM, Tiesman JP, Chaney JG, Aardema MJ. 2004. Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins. Mutat Res 549:5-27.
11. ICH (International Conference on Harmonisation - Safety). 1996. Genotoxicity: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. ICH Harmonised Tripartite Guideline S2(A).
12. ICH (International Conference on Harmonisation - Safety). 2011. Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. ICH Harmonised Tripartite Guideline S2(R1). Retrieved from: http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
13. Islaih M, Halstead BW, Kadura IA, Li B, Reid-Hubbard JL, Flick L, Altizer JL, Thom Deahl J, Monteith DK, Newton RK, Watson DE. 2005. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res 578:100-116.
14. Kerr MK, Churchill GA. 2001. Statistical design and the analysis of gene expression microarray data. Genet Res 77:123-128.
15. Kirkland DJ, Hayashi M, Jacobson-Kram D, Kasper P, Gollapudi B, Muller L, Uno Y. 2011. Summary of major conclusions from the 5th IWGT, Basel, Switzerland, 17-19 August 2009. Mutat Res 723:73-76.
16. Li HH, Hyduke DR, Chen R, Heard P, Aubrecht J, Fornace Jr. AJ. 2015. Development of a toxicogenomics signature for genotoxicity using a dose optimization and informatics strategy in human cells. Environ Mol Mutagen.
17. Magkoufopoulou C, Claessen SM, Tsamou M, Jennen DG, Kleinjans JC, van Delft JH. 2012. A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis 33:1421-1429.
18. Miller RG Jr. 1981. Simultaneous Statistical Inference. New York: Springer-Verlag.
19. Moffat I, Chepelev N, Labib S, Bourdon-Lacombe J, Kuo B, Buick JK, Lemieux F, Williams A, Halappanavar S, Malik A, et al. 2015. Comparison of toxicogenomics and traditional approaches to inform mode of action and points of departure in human health risk assessment of benzo[a]pyrene in drinking water. Crit Rev Toxicol 45:1-43.
20. Muller L, Kikuchi Y, Probst G, Schechtman L, Shimada H, Sofuni T, Tweats D. 1999. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat Res 436:195-225.
21. OECD (Organisation for Economic Co-operation and Development). 2014. Test Guideline (TG) 487. In Vitro Mammalian Cell Micronucleus Test: Organisation for Economic Co-operation and Development. http://www.oecd-ilibrary.org/docserver/download/9714561e.pdf?expires=1422634899&id=id&accname=guest&checksum=A34AEAF21F3BF7A1C7DAE8023C6CC144.
22. Recio L, Shepard KG, Hernandez LG, Kedderis GL. 2012. Dose-response assessment of naphthalene-induced genotoxicity and glutathione detoxication in human TK6 lymphoblasts. Toxicol Sci 126:405-412.
23. Rohrbeck A, Salinas G, Maaser K, Linge J, Salovaara S, Corvi R, Borlak J. 2010. Toxicogenomics applied to in vitro carcinogenicity testing with Balb/c 3T3 cells revealed a gene signature predictive of chemical carcinogens. Toxicol Sci 118:31-41.
24. Shimada T, Kim D, Murayama N, Tanaka K, Takenaka S, Nagy LD, Folkman LM, Foroozesh MK, Komori M, Yamazaki H, Guengerich FP. 2013. Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chem Res Toxicol 26:517-528.
25. Simon P. 2003. Q-Gene: Processing quantitative real-time RT-PCR data. Bioinformatics 19:1439-1440.
26. Thybaud V, Aardema M, Casciano D, Dellarco V, Embry MR, Gollapudi BB, Hayashi M, Holsapple MP, Jacobson-Kram D, Kasper P, MacGregor JT, Rees R. 2007. Relevance and follow-up of positive results in in vitro genetic toxicity assays: an ILSI-HESI initiative. Mutat Res 633:67-79.
27. Tibshirani R, Hastie T, Narasimhan B, Chu G. 2002. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567-6572.